NESS-040C5

NESS-040C5
Clinical data
ATC code	none;
Legal status
Legal status	CA: Schedule II;
Identifiers
	IUPAC name N-(2-isopropyl-5-methylcyclohexyl)-1-(4-methylbenzyl)-1,4-dihydrothieno[3',2':4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide;
CAS Number	1445751-90-5;
PubChem CID	138402821;
UNII	P6H2AAY2GE;
CompTox Dashboard (EPA)	DTXSID201010004 ;
Chemical and physical data
Formula	C27H33N3OS
Molar mass	447.64 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C=C1)=CC=C1CN2C3=C(CC4=C3SC=C4)C(C(NC5CC(C)CCC5C(C)C)=O)=N2;

NESS-040C5 is a potent cannabinoid agonist which was developed for the treatment of glaucoma.^[1] It has reasonable selectivity for the CB₂ receptor subtype, having a CB₂ affinity of 0.4nM, and 25x selectivity over the related CB₁ receptor.^[2]

References

^ Paolo Lazzari et al. Pharmaceutical Compounds. US Patent 8106218
^ Hanus LO, Mechoulam R (2010). "Novel natural and synthetic ligands of the endocannabinoid system". Current Medicinal Chemistry. 17 (14): 1341–59. doi:10.2174/092986710790980096. PMID 20166928.

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

[1] Paolo Lazzari et al. Pharmaceutical Compounds. US Patent 8106218

[2] Hanus LO, Mechoulam R (2010). "Novel natural and synthetic ligands of the endocannabinoid system". Current Medicinal Chemistry. 17 (14): 1341–59. doi:10.2174/092986710790980096. PMID 20166928.

[1]

[2]

Clinical data

ATC code	none
Legal status
Legal status	CA: Schedule II
Identifiers
IUPAC name N-(2-isopropyl-5-methylcyclohexyl)-1-(4-methylbenzyl)-1,4-dihydrothieno[3',2':4,5]cyclopenta[1,2-c]pyrazole-3-carboxamide
CAS Number	1445751-90-5
PubChem CID	138402821
UNII	P6H2AAY2GE
CompTox Dashboard (EPA)	DTXSID201010004
Chemical and physical data
Formula	C₂₇H₃₃N₃OS
Molar mass	447.64 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC(C=C1)=CC=C1CN2C3=C(CC4=C3SC=C4)C(C(NC5CC(C)CCC5C(C)C)=O)=N2

NESS-040C5

See also

References